MCID: PLM129
MIFTS: 72

Pulmonary Disease, Chronic Obstructive

Categories: Respiratory diseases

Aliases & Classifications for Pulmonary Disease, Chronic Obstructive

MalaCards integrated aliases for Pulmonary Disease, Chronic Obstructive:

Name: Pulmonary Disease, Chronic Obstructive 57 76 75 44 38
Chronic Obstructive Pulmonary Disease 38 12 76 37 29 3 15 63
Copd 57 12 75 43 3 63
Pulmonary Disease, Chronic Obstructive, Severe Early-Onset 57 13
Pulmonary Disease, Chronic Obstructive, Susceptibility to 29 6
Chronic Obstructive Airway Disease 12 73
Chronic Obstructive Lung Disease 12 75
Pulmonary Disease, Obstructive, Chronic, Susceptibility to 40
Severe Early-Onset Chronic Obstructive Pulmonary Disease 75
Chronic Obstructive Pulmonary Disease of Horses 73
Pulmonary Disease Chronic Obstructive 55
Upper Respiratory Infections 73
Common Cold 73
Cold 12

Classifications:



Summaries for Pulmonary Disease, Chronic Obstructive

MedlinePlus : 43 COPD (chronic obstructive pulmonary disease) makes it hard for you to breathe. The two main types are chronic bronchitis and emphysema. The main cause of COPD is long-term exposure to substances that irritate and damage the lungs. This is usually cigarette smoke. Air pollution, chemical fumes, or dust can also cause it. At first, COPD may cause no symptoms or only mild symptoms. As the disease gets worse, symptoms usually become more severe. They include A cough that produces a lot of mucus Shortness of breath, especially with physical activity Wheezing Chest tightness Doctors use lung function tests, imaging tests, and blood tests to diagnose COPD. There is no cure. Treatments may relieve symptoms. They include medicines, oxygen therapy, surgery, or a lung transplant. Quitting smoking is the most important step you can take to treat COPD. NIH: National Heart, Lung, and Blood Institute

MalaCards based summary : Pulmonary Disease, Chronic Obstructive, also known as chronic obstructive pulmonary disease, is related to alpha-1-antitrypsin deficiency and respiratory failure, and has symptoms including coughing, fever and pruritus. An important gene associated with Pulmonary Disease, Chronic Obstructive is LINC00229 (Long Intergenic Non-Protein Coding RNA 229
Five of the analyzed lncRNAs (BC038205, BC130595, TUG1, MEG3, and LOC646329) were markedly increased, while five lncRNAs (LOC729178, PLAC2, LOC339529, LINC00229, and SNHG5) were significantly decreased in COPD lung tissues compared with non-COPD lung tiss??
Dysfunction Pattern: Expression [low expression]), and among its related pathways/superpathways are Matrix Metalloproteinases and Rheumatoid arthritis. The drugs Advair and Anoro Ellipta have been mentioned in the context of this disorder. Affiliated tissues include lung, testes and heart, and related phenotype is chronic obstructive pulmonary disease.

OMIM : 57 Chronic obstructive pulmonary disease (COPD) is a common, complex disorder associated with substantial morbidity and mortality. COPD is defined by irreversible airflow obstruction due to chronic bronchitis, emphysema, and/or small airways disease. Airflow obstruction is typically determined by reductions in quantitative spirometric indices, including forced expiratory volume at 1 second (FEV1) and the ratio of FEV1 to forced vital capacity (FVC) (Silverman et al., 2002; Celedon et al., 2004). (606963)

UniProtKB/Swiss-Prot : 75 Pulmonary disease, chronic obstructive: A common, complex disorder defined by irreversible airflow obstruction due to chronic bronchitis, emphysema, and/or small airways disease. Airflow obstruction is typically determined by reductions in quantitative spirometric indices, including forced expiratory volume at 1 second (FEV1) and the ratio of FEV1 to forced vital capacity (FVC).

PubMed Health : 63 About copd: COPD, or chronic obstructive pulmonary (PULL-mun-ary) disease, is a progressive disease that makes it hard to breathe. "Progressive" means the disease gets worse over time.COPD can cause coughing that produces large amounts of mucus (a slimy substance), wheezing, shortness of breath, chest tightness, and other symptoms.Cigarette smoking is the leading cause of COPD. Most people who have COPD smoke or used to smoke. Long-term exposure to other lung irritants—such as air pollution, chemical fumes, or dust—also may contribute to COPD.

Wikipedia : 76 Chronic obstructive pulmonary disease (COPD) is a type of obstructive lung disease characterized by... more...

Related Diseases for Pulmonary Disease, Chronic Obstructive

Diseases related to Pulmonary Disease, Chronic Obstructive via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 182)
# Related Disease Score Top Affiliating Genes
1 alpha-1-antitrypsin deficiency 33.8 CXCL8 ELANE SERPINA1
2 respiratory failure 33.6 CRP CXCL8 ELANE PDE4A SERPINA1 TNF
3 lung disease 33.5 CXCL8 ELANE PDE4A SERPINA1 TNF
4 asthma 32.2 ADRB2 CXCL8 ELANE HDAC2 MMP1 PDE4A
5 bronchitis 32.1 CXCL8 ELANE SERPINA1 TNF
6 pneumonia 32.0 CRP CXCL8 ELANE TNF
7 bronchiectasis 31.9 CXCL8 ELANE SERPINA1
8 pulmonary emphysema 31.9 ELANE HMOX1 MMP1 SERPINA1
9 sleep apnea 31.4 CRP CXCL8 TNF
10 periodontitis 31.3 CRP CXCL8 MMP1 TNF
11 pulmonary fibrosis, idiopathic 31.3 CXCL8 ELANE MMP1 TNF
12 cystitis 31.2 CRP CXCL8 TNF
13 chlamydia 31.2 CRP CXCL8 TNF
14 periodontal disease 31.1 CRP CXCL8 ELANE MMP1 TNF
15 cystic fibrosis 31.0 ADRB2 CXCL8 ELANE SERPINA1
16 coloboma, ocular, autosomal dominant 11.6
17 esophagus squamous cell carcinoma 11.2 MEG3 TUG1
18 arthus reaction 11.2 ELANE HMOX1 TNF
19 status asthmaticus 11.2 ADRB2 CXCL8 ELANE
20 cardiac rupture 11.2 CRP CXCL8 ELANE
21 pulpitis 11.2 CXCL8 MMP1 TNF
22 pyoderma 11.2 CXCL8 MMP1 TNF
23 aspergillosis 11.2
24 viral meningitis 11.2 CRP CXCL8 SERPINA1
25 louse-borne relapsing fever 11.2 CRP CXCL8 TNF
26 pleural disease 11.2
27 multifocal atrial tachycardia 11.2
28 lymph node disease 11.2 CRP MMP1 TNF
29 perinatal necrotizing enterocolitis 11.2 CRP CXCL8 TNF
30 acute respiratory distress syndrome 11.2 CXCL8 ELANE TNF
31 mycobacterium abscessus 11.2 CXCL8 HMOX1 SERPINA1 TNF
32 pleurisy 11.1 CRP CXCL8 TNF
33 uterine anomalies 11.1 CRP CXCL8 TNF
34 leptospirosis 11.1 CRP CXCL8 TNF
35 adult respiratory distress syndrome 11.1 CXCL8 ELANE TNF
36 brucellosis 11.1 CRP CXCL8 TNF
37 pyelonephritis 11.1 CRP CXCL8 TNF
38 appendicitis 11.1 CRP CXCL8 TNF
39 tungiasis 11.1 CXCL8 TNF
40 gingivitis 11.1 CXCL8 ELANE TNF
41 carotid stenosis 11.1 CRP MMP1 TNF
42 leukocyte disease 11.1 CRP ELANE TNF
43 streptococcal toxic-shock syndrome 11.1 CXCL8 TNF
44 pulmonary edema 11.1 CRP CXCL8 HMOX1 TNF
45 bacterial meningitis 11.1 CRP CXCL8 TNF
46 bone inflammation disease 11.1 CRP CXCL8 MMP1 TNF
47 chorioamnionitis 11.1 CRP CXCL8 ELANE TNF
48 gastroenteritis 11.1 CRP CXCL8 TNF
49 synovitis 11.1 CRP CXCL8 MMP1 TNF
50 endocarditis 11.1 CRP CXCL8 TNF

Comorbidity relations with Pulmonary Disease, Chronic Obstructive via Phenotypic Disease Network (PDN):


Bronchitis Heart Disease

Graphical network of the top 20 diseases related to Pulmonary Disease, Chronic Obstructive:



Diseases related to Pulmonary Disease, Chronic Obstructive

Symptoms & Phenotypes for Pulmonary Disease, Chronic Obstructive

Clinical features from OMIM:

606963

Human phenotypes related to Pulmonary Disease, Chronic Obstructive:

32
# Description HPO Frequency HPO Source Accession
1 chronic obstructive pulmonary disease 32 HP:0006510

UMLS symptoms related to Pulmonary Disease, Chronic Obstructive:


coughing, fever, pruritus, snoring, tinnitus, sore throat, vertigo/dizziness, equilibration disorder, rhinorrhea, catarrh, angina pectoris, tremor, upper respiratory tract inflammation

Drugs & Therapeutics for Pulmonary Disease, Chronic Obstructive

PubMedHealth treatment related to Pulmonary Disease, Chronic Obstructive: 63

COPD has no cure yet. However, lifestyle changes and treatments can help you feel better, stay more active, and slow the progress of the disease.The goals of COPD treatment include:Relieving your symptomsSlowing the progress of the diseaseImproving your exercise tolerance (your ability to stay active)Preventing and treating complicationsImproving your overall healthTo assist with your treatment, your family doctor may advise you to see a pulmonologist. This is a doctor who specializes in treating lung disorders.

FDA approved drugs:

(show all 16)
# Drug Name Active Ingredient(s) 18 Company Approval Date
1
Advair 18 FLUTICASONE PROPIONATE; SALMETEROL XINAFOATE GlaxoSmithKline August 2000
2
Anoro Ellipta 18 UMECLIDINIUM BROMIDE; VILANTEROL TRIFENATATE GlaxoSmithKline December of 2013
3
Arcapta 18 INDACATEROL MALEATE Novartis July 2011
4
Breo Ellipta 18 FLUTICASONE FUROATE; VILANTEROL TRIFENATATE GlaxoSmithKline May 2013
5
Brovana 18 ARFORMOTEROL TARTRATE Sepracor in October 2006
6
Daliresp 18 ROFLUMILAST Forest Pharmaceuticals February 2011
7
DuoNeb 18 ALBUTEROL SULFATE; IPRATROPIUM BROMIDE Dey Laboratories March 2001
8
Foradil Aerolizer 18 FORMOTEROL FUMARATE Novartis February 2001 (asthma, bronchospasm); September 2001 (COPD)
9
Incruse Ellipta 18 UMECLIDINIUM BROMIDE GlaxoSmithKline May 2014
10
Rayos 18 PREDNISONE Horizon Pharma July of 2012
11
Spiriva HandiHaler 18 TIOTROPIUM BROMIDE Boehringer Ingelheim February 2004
12
Stiolto Respimat 18 OLODATEROL HYDROCHLORIDE; TIOTROPIUM BROMIDE Boehringer Ingelheim May 2015
13
Striverdi Respimat 18 OLODATEROL HYDROCHLORIDE Boehringer Ingelheim July 2014
14
Tudorza Pressair 18 ACLIDINIUM BROMIDE Forest Laboratories July 2012
15
Utibron Neohaler 18 GLYCOPYRROLATE ; INDACATEROL MALEATE Novartis October 2015
16
Xopenex 18 LEVALBUTEROL HYDROCHLORIDE Sepracor February 2002

Drugs for Pulmonary Disease, Chronic Obstructive (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 647)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Azithromycin Approved Phase 4,Phase 3,Phase 2,Not Applicable,Early Phase 1 83905-01-5 55185 447043
2
Caspofungin Approved Phase 4 179463-17-3, 162808-62-0 468682 2826718
3
Miconazole Approved, Investigational, Vet_approved Phase 4,Phase 2,Phase 1 22916-47-8 4189
4
Fluticasone Approved, Experimental, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 90566-53-3 62924
5
Iloprost Approved, Investigational Phase 4,Phase 2,Phase 1,Not Applicable 78919-13-8 6443959
6
Terbutaline Approved Phase 4,Phase 3,Not Applicable 23031-25-6 5403
7
Prednisone Approved, Vet_approved Phase 4,Phase 3,Phase 2,Not Applicable 53-03-2 5865
8
Metoprolol Approved, Investigational Phase 4,Phase 3,Not Applicable 37350-58-6, 51384-51-1 4171
9
Budesonide Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 51333-22-3 63006 5281004
10
Nitric Oxide Approved Phase 4,Phase 2,Phase 1,Not Applicable,Early Phase 1 10102-43-9 145068 160954
11
Simvastatin Approved Phase 4,Phase 3,Phase 1 79902-63-9 54454
12
Mannitol Approved, Investigational Phase 4,Not Applicable 69-65-8 453 6251
13
Dexmedetomidine Approved, Vet_approved Phase 4,Not Applicable 113775-47-6 68602 5311068
14
Ipratropium Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 22254-24-6, 60205-81-4 43232
15
Doxycycline Approved, Investigational, Vet_approved Phase 4,Phase 3,Not Applicable 564-25-0 54671203
16
Cefuroxime Approved Phase 4,Phase 3 55268-75-2 5361202 5479529
17
Ciprofloxacin Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 85721-33-1 2764
18
Clarithromycin Approved Phase 4,Phase 3 81103-11-9 84029
19
Moxifloxacin Approved, Investigational Phase 4,Phase 3,Phase 1 354812-41-2, 151096-09-2 152946
20
Penicillin G Approved, Vet_approved Phase 4 61-33-6 5904
21
Piperacillin Approved Phase 4,Not Applicable 66258-76-2 43672
22
Salmon Calcitonin Approved, Investigational Phase 4,Phase 2,Phase 3,Not Applicable 47931-85-1 16129616
23
Tazobactam Approved Phase 4,Not Applicable 89786-04-9 123630
24
Acetylcysteine Approved, Investigational Phase 4,Phase 1,Phase 2,Not Applicable 616-91-1 12035
25
Theophylline Approved Phase 4,Phase 3,Phase 2,Not Applicable 58-55-9 2153
26
Methylprednisolone Approved, Vet_approved Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable 83-43-2 6741
27
Prednisolone Approved, Vet_approved Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable 50-24-8 5755
28
Fenoterol Approved, Investigational Phase 4,Phase 3,Not Applicable 13392-18-2 3343
29
Epinephrine Approved, Vet_approved Phase 4,Not Applicable 51-43-4 5816
30
Menthol Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 2216-51-5 16666
31
Racepinephrine Approved Phase 4,Not Applicable 329-65-7 838
32
Estradiol Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 1 50-28-2 5757
33 Estradiol valerate Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 1 979-32-8
34
Ethinyl Estradiol Approved Phase 4,Phase 3,Phase 1 57-63-6 5991
35
Norgestimate Approved, Investigational Phase 4,Phase 3,Phase 1 35189-28-7 6540478
36
Polyestradiol phosphate Approved Phase 4,Phase 3,Phase 1 28014-46-2
37
Levofloxacin Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 100986-85-4 149096
38
Ofloxacin Approved Phase 4,Phase 3,Phase 2,Phase 1 82419-36-1 4583
39
Benzocaine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 1994-09-7, 94-09-7 2337
40
Morphine Approved, Investigational Phase 4,Phase 3,Phase 2,Not Applicable 57-27-2 5288826
41
Metformin Approved Phase 4 657-24-9 14219 4091
42
Adenosine Approved, Investigational Phase 4,Phase 2,Not Applicable 58-61-7 60961
43
Regadenoson Approved, Investigational Phase 4 313348-27-5 219024
44
Cortisone acetate Approved, Investigational Phase 4 1950-04-4, 50-04-4 5745
45
Amoxicillin Approved, Vet_approved Phase 4,Phase 3 26787-78-0 33613
46 Olodaterol Approved Phase 4,Phase 3,Phase 2,Phase 1 868049-49-4
47
Fosinopril Approved Phase 4 98048-97-6 55891
48
Carvedilol Approved, Investigational Phase 4 72956-09-3 2585
49
Dexamethasone Approved, Investigational, Vet_approved Phase 4 50-02-2 5743
50
Acetazolamide Approved, Vet_approved Phase 4,Phase 3 59-66-5 1986

Interventional clinical trials:

(show top 50) (show all 3229)
# Name Status NCT ID Phase Drugs
1 Prophylactic Antibiotic Treatment of Patients With Chronic Obstructive Lung Disease (COLD) Unknown status NCT00132860 Phase 4 azithromycin
2 Inhaler Lung Deposition in Chronic Obstructive Pulmonary Disease (COPD) Unknown status NCT01721291 Phase 4 SALBUTAMOL
3 Efficacy and Safety of Caspofungin for Invasive Pulmonary Aspergillosis Underlying Chronic Obstructive Pulmonary Disease Unknown status NCT01499433 Phase 4 caspofungin
4 Seasonal Influenza Vaccine, Quadrivalent Versus Trivalent in Patients With Advanced Chronic Obstructive Pulmonary Disease Unknown status NCT02563184 Phase 4
5 Randomized, Double-blind, Placebo-controlled Study to Evaluate the Effect of Roflumilast on Endothelial Function in Patients With Chronic Obstructive Pulmonary Disease Unknown status NCT01595750 Phase 4 Roflumilast 500;Placebo
6 Comparing Treatment Efficacy With HD/MD Flu Plus Sal in Chronic Obstructive Pulmonary Disease (COPD) Patients Unknown status NCT01131806 Phase 4 fluticasone/ salmeterol 125/25 mcg/puff;fluticasone/ salmeterol 250/25 mcg/puff
7 Inhaled Iloprost for Disproportionate Pulmonary Hypertension in Chronic Obstructive Pulmonary Disease (COPD) Unknown status NCT01116063 Phase 4 Inhaled iloprost
8 Efficacy and Safety of Tulobuterol Patch Combined With Tiotropium Bromide for Relieving Dyspnea Symptom of Chronic Obstructive Pulmonary Disease Unknown status NCT01465906 Phase 4 tulobuterol;Tiotropium Bromide;tiotropium bromide
9 The Role of Opinion Leaders in Enhancing Evidence-based Care After Chronic Obstructive Pulmonary Disease (COPD) Emergency Department (ED) Visits Unknown status NCT01107613 Phase 4
10 Metoprolol and Formoterol in Chronic Obstructive Pulmonary Disease (COPD) Unknown status NCT00288548 Phase 4 Metoprolol
11 Exacerbation Prevention GOLD IV COPD With Non Invasive Mechanical Ventilation Unknown status NCT01481727 Phase 4
12 Can Advair and Flovent Reduce Systemic Inflammation Related to Chronic Obstructive Pulmonary Disease (COPD)? A Multi-Center Randomized Controlled Trial Unknown status NCT00120978 Phase 4 Advair;Flovent
13 Small Airways Evaluation and Treatment Unknown status NCT02526758 Phase 4 beclomethasone;formoterol;budesonide
14 Strategy to Improve Adherence of Roflumilast Unknown status NCT02018432 Phase 4 Roflumilast escalation dosage;Roflumilast conventional dosage
15 Pulmonary Gas Exchange Response to Indacaterol in COPD Unknown status NCT02547558 Phase 4 Indacaterol
16 Exhaled NO Based Treatment of Chronic Obstructive Pulmonary Disease (COPD), ICS/LABA Versus LAMA Unknown status NCT02546349 Phase 4 fluticasone/salmeterol, tiotropium
17 Simvastatin in Chronic Obstructive Pulmonary Disease (COPD) Unknown status NCT00680641 Phase 4 Simvastatin;Placebo
18 Predictor for an Additional Benefit of Inhaled Corticosteroid in Patients Treated With Tiotropium for COPD Unknown status NCT00860938 Phase 4 Budesonide
19 Placebo Controlled Evaluation of Sedation and Physiological Response to Intranasal Dexmedetomidine in Severe COPD Unknown status NCT02773797 Phase 4 IN-DEX 1.0 mcg/kg, intranasal saline;IN-DEX 1.5 mcg/kg, intranasal saline;Placebo - Saline
20 The Efficacy and Safety of Salmeterol/Fluticasone Propionate vs Atropium/Albuterol in Patients COPD Unknown status NCT01243788 Phase 4 Salmeterol/Fluticasone Propionate
21 Description of the Ability to Learn How to Handle Inhaler Devices in COPD Unknown status NCT02813200 Phase 4 Seretide® Diskus® 500/550 μg;Ultibro® Breezhaler® 110/50 μg;Spiriva® Respimat® 2,5 μg
22 Doxycycline and Airway Inflammation in Chronic Obstructive Pulmonary Disease (COPD) Unknown status NCT00857038 Phase 4 Doxycycline;Placebo
23 Home Non Invasive Ventilation (NIV) Treatment for COPD-patients After a NIV-treated Exacerbation Unknown status NCT01513655 Phase 4
24 Effects of Nutritional Supplementation in Malnourished Patients in Stable COPD Unknown status NCT02197871 Phase 4
25 Comparing Fluticasone-Salmeterol in Chronic Obstructive Pulmonary Disease (COPD) and Sleep Unknown status NCT00731770 Phase 4 fluticasone/salmeterol 250/50;placebo
26 Acute Effect of Sildenafil on Exercise Tolerance and Functional Capacity in COPD, IPF and Post Pneumonectomy Patients Unknown status NCT01382368 Phase 4 Sildenafil
27 An Efficacy Study of BCS Clearing the Oral Colonized Bacterium in Hospitalized Patients With COPD Unknown status NCT02269800 Phase 4 Benzalkonium chloride solution;Normal saline
28 EUROPT Clinical Trial to Study the Efficacy of One-Way Valve Implantation (New Treatment Algorithm) in Patients With Heterogeneous Emphysema Unknown status NCT00730301 Phase 4
29 Sunovion Brovana Versus Serevent Inspiratory Capacity High Resolution Computed Tomography Unknown status NCT01361984 Phase 4 Nebulized arformoterol;Salmeterol
30 Efficacy of Bronchial Thermoplasty in Korean Unknown status NCT02031263 Phase 4
31 LTOT in COPD Patients With Moderate Chronic Hypoxemia and Chronic Heart Failure Unknown status NCT00668408 Phase 4
32 Effects of Exercise Training on Systemic Inflammation an Muscle Repair According to the Obstructive Chronic Pulmonary Disease (COPD) Phenotype Unknown status NCT01431625 Phase 4
33 Effect of Noninvasive Ventilation on Physical Activity and Inflammation in COPD Patients Unknown status NCT01037387 Phase 4 Control
34 Evaluate the Effects of Formoterol and Beclomethasone Dipropionate Combination Therapy on Small Airways Function Unknown status NCT01466712 Phase 4 Tiotropium + formoterol/beclometasone;tiotropium + placebo
35 Procalcitonin as a Marker of Antibiotic Therapy in Patients With Lower Respiratory Tract Infections Unknown status NCT02171338 Phase 4
36 Transfusion Strategies in Weaning Patients Unknown status NCT01256645 Phase 4
37 Evaluation and Reconditioning of Marginal Lung Donors to Transplantation by ex Vivo Lung Perfusion Unknown status NCT01353105 Phase 4
38 Comparative Study of Non-Invasive Mask Ventilation vs Cuirass Ventilation in Patients With Acute Respiratory Failure. Unknown status NCT00331656 Phase 4
39 AeriSeal System in Patients With Advanced Upper Lobe Predominant Emphysema and Collateral Ventilation Unknown status NCT01460108 Phase 4
40 Effect of Long-term, High-dose N-acetylcysteine on Exacerbations of Bronchiectaisis Unknown status NCT02088216 Phase 4 N-acetylcysteine;Placebo
41 Surfactant Administration During Spontaneous Breathing Unknown status NCT01329432 Phase 4
42 Airway Clearance for Prevention of COPD Exacerbation Unknown status NCT00181207 Phase 4
43 A 16-Week Study to Evaluate the Effect of Advair DISKUS™ 250/50mcg on Arterial Stiffness in Subjects With Chronic Obstructive Pulmonary Disease (COPD) Completed NCT00857766 Phase 4 ADVAIR DISKUS™ 250/50mcg
44 Metformin in Chronic Obstructive Pulmonary Disease Completed NCT01247870 Phase 4 Metformin;Placebo
45 Validation of a New Shortness of Breath With Daily Activities Questionnaire in Patients With Chronic Obstructive Pulmonary Disease Completed NCT00984659 Phase 4 Fluticasone propionate/salmeterol combination product;Salmeterol;Placebo
46 Inhaled Corticosteroid Withdrawal in Patients With Chronic Obstructive Pulmonary Disease Completed NCT00975195 Phase 4 tiotropium inhalation;salmeterol xinafoate;fluticasone propionate;placebo matched for fluticasone propionate
47 Efficacy and Tolerability of Symbicort as an add-on Treatment to Spiriva Compare With Spiriva Alone in Patients With Severe Chronic Obstructive Pulmonary Disease (COPD) Completed NCT01397890 Phase 4 Budesonide/formoterol (Symbicort® Turbuhaler®);Tiotropium (SpirivaTM)
48 Advair® DISKUS® Versus Serevent® DISKUS® For Chronic Obstructive Pulmonary Disease Exacerbations Completed NCT00115492 Phase 4 Fluticasone Propionate/Salmeterol Combination Product;Salmeterol
49 ADVAIR® DISKUS® Inhaler (Fluticasone Propionate/Salmeterol) Versus SEREVENT® DISKUS® Inhaler (Salmeterol) For The Treatment Of Chronic Obstructive Pulmonary Disease Exacerbations. ADVAIR® DISKUS® Inhaler and SEREVENT® DISKUS® Inhaler Are Trademarks of the Completed NCT00144911 Phase 4 Salmeterol;Fluticasone Propionate/Salmeterol Combination Product
50 Preference Attributes of ELLIPTA Dry Powder Inhaler (DPI) and HANDIHALER DPI in Subjects With Chronic Obstructive Pulmonary Disease (COPD) Completed NCT02786927 Phase 4 Placebo ELLIPTA device;Placebo capsules for use in HANDIHALER device

Search NIH Clinical Center for Pulmonary Disease, Chronic Obstructive

Inferred drug relations via UMLS 73 / NDF-RT 51 :


Cell-based therapeutics:


LifeMap Discovery
Data from LifeMap, the Embryonic Development and Stem Cells Database
Stem-cell-based therapeutic approaches for Pulmonary Disease, Chronic Obstructive:
Adipocell
Bone marrow-derived mononuclear cells for chronic obstructive pulmonary disease
Prochymal
StempeucelCOPD
Embryonic/Adult Cultured Cells Related to Pulmonary Disease, Chronic Obstructive:
Bone marrow-derived mononuclear cells PMIDs: 21653527 23054962 21311694
Bone marrow-derived mesenchymal stem cells PMIDs: 23172272 21653527
Bone marrow-derived mesenchymal stem cells (Stempeucel PMIDs: 18720444

Cochrane evidence based reviews: pulmonary disease, chronic obstructive

Genetic Tests for Pulmonary Disease, Chronic Obstructive

Genetic tests related to Pulmonary Disease, Chronic Obstructive:

# Genetic test Affiliating Genes
1 Chronic Obstructive Pulmonary Disease 29 HMOX1 MMP1 SERPINA1
2 Pulmonary Disease, Chronic Obstructive, Susceptibility to 29

Anatomical Context for Pulmonary Disease, Chronic Obstructive

MalaCards organs/tissues related to Pulmonary Disease, Chronic Obstructive:

41
Lung, Testes, Heart, Endothelial, Bone, Neutrophil, Smooth Muscle

Publications for Pulmonary Disease, Chronic Obstructive

Articles related to Pulmonary Disease, Chronic Obstructive:

(show top 50) (show all 2672)
# Title Authors Year
1
MiR-3202 protects smokers from chronic obstructive pulmonary disease through inhibiting FAIM2: An in vivo and in vitro study. ( 29208459 )
2018
2
Analysis of volatile organic compounds in the breath of patients with stable or acute exacerbation of chronic obstructive pulmonary disease. ( 29295966 )
2018
3
Association between Genetic Variations of MERTK and Chronic Obstructive Pulmonary Disease in Koreans. ( 29359540 )
2018
4
Pulmonary Hypertension Related to Chronic Obstructive Pulmonary Disease and Diffuse Parenchymal Lung Disease: A Focus on Right Ventricular (Dys)Function. ( 29966637 )
2018
5
COPD in Primary Care: Key Considerations for Optimized Management: Anxiety and Depression in Chronic Obstructive Pulmonary Disease: Recognition and Management. ( 29443332 )
2018
6
Emphysematous and Nonemphysematous Gas Trapping in Chronic Obstructive Pulmonary Disease: Quantitative CT Findings and Pulmonary Function. ( 29361243 )
2018
7
Predictors of exacerbation risk and response to budesonide in patients with chronic obstructive pulmonary disease: a post-hoc analysis of three randomised trials. ( 29331313 )
2018
8
Chronic Obstructive Pulmonary Disease Exacerbations Are Influenced by Gastroesophageal Reflux Disease. ( 29428028 )
2018
9
Chronic obstructive pulmonary disease-induced autonomic dysfunction may be associated with cerebral blood flow regulation and brain function. ( 29978508 )
2018
10
Perception and Awareness of chronic obstructive pulmonary disease, Chronic Bronchitis and Pulmonary Emphysema in the Spanish Urban Population. ( 29428681 )
2018
11
A Comparison of Pain, Fatigue, Dyspnea and their Impact on Quality of Life in Pulmonary Rehabilitation Participants with Chronic Obstructive Pulmonary Disease. ( 29227712 )
2018
12
Relationship between heart failure, concurrent chronic obstructive pulmonary disease and beta-blocker use: a Danish nationwide cohort study. ( 29159953 )
2018
13
Effectiveness of a respiratory rehabilitation programme in patients with chronic obstructive pulmonary disease. ( 29287828 )
2018
14
Features of Chronic Obstructive Pulmonary Disease as Predictors of Lung Cancer. ( 29452098 )
2018
15
Pulmonary Embolism Among Patients With Acute Exacerbation Of Chronic Obstructive Pulmonary Disease: Implications For Emergency Medicine. ( 29945817 )
2018
16
Impact of bronchiectasis on outcomes of hospitalized patients with acute exacerbation of chronic obstructive pulmonary disease: A propensity matched analysis. ( 29915333 )
2018
17
Ventilator-dependent pulmonary nocardiosis in a patient with chronic obstructive pulmonary disease. ( 29319037 )
2018
18
Major Depression in Long-Term Oxygen Therapy Dependent Chronic Obstructive Pulmonary Disease. ( 27220917 )
2018
19
Significance of Low-Attenuation Cluster Analysis on Quantitative CT in the Evaluation of Chronic Obstructive Pulmonary Disease. ( 29354010 )
2018
20
Whole-genome methylation profiling of peripheral blood mononuclear cell for acute exacerbations of chronic obstructive pulmonary disease treated with corticosteroid. ( 29329142 )
2018
21
An exploration of pain experiences and their meaning in people with chronic obstructive pulmonary disease. ( 29319390 )
2018
22
Self-management strategies in chronic obstructive pulmonary disease: a first step toward personalized medicine. ( 29278544 )
2018
23
What Can We Apply to Manage Acute Exacerbation of Chronic Obstructive Pulmonary Disease with Acute Respiratory Failure? ( 29372630 )
2018
24
Linear rheology as a potential monitoring tool for sputum in patients with Chronic Obstructive Pulmonary Disease (COPD). ( 29278868 )
2018
25
Prevalence of chronic obstructive pulmonary disease in the global population with HIV: a systematic review and meta-analysis. ( 29254748 )
2018
26
Gastroesophageal reflux symptoms and nasal symptoms affect the severity of bronchitis symptoms in patients with chronic obstructive pulmonary disease. ( 29773294 )
2018
27
Comparative analysis of salivary sialic acid levels in patients with chronic obstructive pulmonary disease and chronic periodontitis patients: A biochemical study. ( 29442082 )
2018
28
Pharmacodynamics, pharmacokinetics and safety of revefenacin (TD-4208), a long-acting muscarinic antagonist, in patients with chronic obstructive pulmonary disease (COPD): Results of two randomized, double-blind, phase 2 studies. ( 28987804 )
2018
29
Study of inflammatory markers and BODE index in chronic obstructive pulmonary disease. ( 29319032 )
2018
30
Effects of telephone support on exercise capacity and quality of life in patients with chronic obstructive pulmonary disease: a meta-analysis. ( 29320895 )
2018
31
"At First I Couldn't Catch My Breath": Process and Strategies for Managing Chronic Obstructive Pulmonary Disease. ( 29214821 )
2018
32
Unpredictable episodic breathlessness in patients with advanced chronic obstructive pulmonary disease and lung cancer: a qualitative study. ( 29046956 )
2018
33
Cost-effectiveness of FreeO<sub>2</sub>in patients with chronic obstructive pulmonary disease hospitalised for acute exacerbations: analysis of a pilot study in Quebec. ( 29362258 )
2018
34
Obesity and Severity of Acute Exacerbation of Chronic Obstructive Pulmonary Disease. ( 29053337 )
2018
35
Azithromycin Pharmacodynamics against Persistent Haemophilus influenzae in Chronic Obstructive Pulmonary Disease. ( 29180527 )
2018
36
Positive end expiratory pressure titration guided by plateau pressure in chronic obstructive pulmonary disease patients. ( 27805309 )
2018
37
Behavioural modes of adherence to inspiratory muscle training in people with chronic obstructive pulmonary disease: a grounded theory study. ( 29303008 )
2018
38
Role of Domiciliary Noninvasive Ventilation in Chronic Obstructive Pulmonary Disease Patients Requiring Repeated Admissions with Acute Type II Respiratory Failure: A Prospective Cohort Study. ( 29962738 )
2018
39
Reporting of pain by people with chronic obstructive pulmonary disease (COPD): comparative results from the HUNT3 population-based survey. ( 29370850 )
2018
40
Changes in IgA protease expression are conferred by changes in genomes during persistent infection by nontypeable <i>Haemophilus influenzae</i> in chronic obstructive pulmonary disease. ( 29760213 )
2018
41
Anti-inflammatory effects of trans-anethole in a mouse model of chronic obstructive pulmonary disease. ( 28511344 )
2017
42
Neutrophil-mediated IL-6 receptor trans-signaling and the risk of chronic obstructive pulmonary disease and asthma. ( 28334838 )
2017
43
The pharmacotherapy preferred by doctors in treatment of patients diagnosed with asthma or chronic obstructive pulmonary disease or allergic rhinitis and concomitant diseases: an epidemiological analysis. ( 28507495 )
2017
44
Comparison of the role of HHIP SNPs in susceptibility to chronic obstructive pulmonary disease between Chinese Han and Mongolian populations. ( 28939338 )
2017
45
Influenza vaccination and risk of respiratory failure in patients with chronic obstructive pulmonary disease: A nationwide population-based case-cohort study. ( 28927683 )
2017
46
Clinical significance of chronic obstructive pulmonary disease in patients undergoing elective total arch replacement: analysis based on the Japan Adult Cardiovascular Surgery Database. ( 28158508 )
2017
47
EPHX1 Y113H polymorphism is associated with increased risk of chronic obstructive pulmonary disease in Kazakhstan population. ( 28464990 )
2017
48
Effect of Fluticasone Furoate and Vilanterol on Exacerbations of Chronic Obstructive Pulmonary Disease in Patients with Moderate Airflow Obstruction. ( 27767328 )
2017
49
Body mass index change in gastrointestinal cancer and chronic obstructive pulmonary disease is associated with Dedicator of Cytokinesis 1. ( 28044437 )
2017
50
Assessment of regional emphysema, air-trapping and Xenon-ventilation using dual-energy computed tomography in chronic obstructive pulmonary disease patients. ( 27882425 )
2017